[Other] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in chemotherapy-naive patients (CN-pts) with metastatic castration resistant prostate cancer (mCRPC).

Closed

onconica89 Post time 2022-8-15 03:14:44 | Show all posts |Read mode

Reward50points

journal：Journal of Clinical Oncology

Authors：Avivit Peer; Avivit Neumann; Avishay Sella; Eli Rosenbaum; Victoria Neiman; Maya Gottfried; Iryna Kuchuk; Svetlana Kovel; David Sarid; Eliahu Gez; Wilmosh Mermershtain; Keren Rouvinov; Michael Anthony Carducci; Mario A. Eisenberger; Victoria J. Sinibaldi; Raanan Berger; Daniel Keizman

Published date：2016-1-10

DOI：10.1200/jco.2016.34.2_suppl.260

Article link：http://dx.doi.org/10.1200/jco.2016.34.2_suppl.260

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

onconica89 Lv.2

Junior Member

post
reply
points
40

[Other] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in chemotherapy-naive patients (CN-pts) with metastatic castration resistant prostate cancer (mCRPC).

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in chemotherapy-naive patients (CN-pts) with metastatic castration resistant prostate cancer (mCRPC). Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in chemotherapy-naive patients (CN-pts) with metastatic castration resistant prostate cancer (mCRPC).